2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey
Wickersham JA, Meyer JP, Shenoi S, Altice FL, Barakat LA, Virata M, Olivares M, Maviglia F, Khati A, Shrestha R. Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers In Medicine 2022, 9: 886936. PMID: 35847816, PMCID: PMC9280331, DOI: 10.3389/fmed.2022.886936.Peer-Reviewed Original ResearchCOVID-19 infectionCOVID-19 vaccineCOVID-19Undetectable HIV viral loadCOVID-19 vaccination uptakeAnnual influenza vaccinationHIV viral loadVaccine-related concernsNational surveyHIV careInfluenza vaccinationVaccination uptakeViral loadVaccination programSevere diseasePWHVaccineHIVInfectionIntensive outreach effortsTotal populationUnited StatesParticipantsAnnual incomeVast majorityCOVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey
Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.Peer-Reviewed Original ResearchCOVID-19 vaccine hesitancyVaccine hesitancySevere COVID-19 diseaseMean timeSample of PWHCells/mm3COVID-19 historyVaccine-related concernsGreater vaccine hesitancyCOVID-19 vaccineCOVID-19COVID-19 diseaseLower vaccine hesitancyCross-sectional online surveyCD4 countAssociated FactorsSide effectsHIVKey populationsPWHMultivariate linear regressionVaccineCOVID-19 epidemicHesitancyMost participants
2021
Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV
Tuan JJ, Zapata H, Critch‐Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineCOVID-19 vaccinationFirst doseSeroconversion ratesSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionYale New Haven Health SystemPrior COVID-19 infectionSyndrome coronavirus 2 infectionSafe COVID-19 vaccineIntegrase strand transfer inhibitorsAnti-spike IgGPositive IgG responseTwo-dose seriesCoronavirus 2 infectionVaccine-induced immunityDurability of protectionCOVID-19 infectionStrand transfer inhibitorsAntiretroviral regimenBNT162b2 vaccineNew seroconversionsPositive IgGQualitative antibody